Zhou Minghao, Xu Keyang, Ge Jianxian, Luo Xingnian, Wu Mengyao, Wang Ning, Zeng Jianfeng
Center for Molecular Imaging and Nuclear Medicine, State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, China.
Int J Mol Sci. 2024 Dec 4;25(23):13042. doi: 10.3390/ijms252313042.
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra and the accumulation of α-synuclein in the brain. Ferroptosis, a recently identified form of regulated cell death, is critical in PD pathogenesis due to its association with iron deposition, overproduction of reactive oxygen species, iron-dependent lipid peroxidation and impaired lipid peroxidation clearance. This cell death mechanism is closely linked to several pathogenic processes in PD, including α-synuclein aggregation, oxidative stress, mitochondrial dysfunction, microglia-induced neuroinflammation, and neuromelanin accumulation. Given the significant role of ferroptosis in these mechanisms, there is increasing interest in targeting ferroptosis for PD treatment. Several drugs have shown potential in alleviating PD symptoms by inhibiting ferroptosis. This review aims to consolidate current knowledge on ferroptosis in PD and assess the therapeutic potential of anti-ferroptosis drugs, highlighting promising directions for future research and clinical applications.
帕金森病（PD）是一种常见的神经退行性疾病，其特征是黑质中多巴胺能神经元的丧失以及大脑中α-突触核蛋白的积累。铁死亡是最近发现的一种程序性细胞死亡形式，由于其与铁沉积、活性氧的过度产生、铁依赖性脂质过氧化以及脂质过氧化清除受损有关，在帕金森病的发病机制中起关键作用。这种细胞死亡机制与帕金森病的几个致病过程密切相关，包括α-突触核蛋白聚集、氧化应激、线粒体功能障碍、小胶质细胞诱导的神经炎症和神经黑色素积累。鉴于铁死亡在这些机制中的重要作用，针对铁死亡进行帕金森病治疗的兴趣日益增加。几种药物已显示出通过抑制铁死亡来缓解帕金森病症状的潜力。本综述旨在整合目前关于帕金森病中铁死亡的知识，并评估抗铁死亡药物的治疗潜力，突出未来研究和临床应用的有前景的方向。
